Eduard Montanya

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/8387085/publications.pdf

Version: 2024-02-01

71 papers	4,847 citations	236612 25 h-index	106150 65 g-index
72 all docs	72 docs citations	72 times ranked	4776 citing authors

#	Article	IF	Citations
1	Liraglutide once a day versus exenatide twice a day for type 2 diabetes: a 26-week randomised, parallel-group, multinational, open-label trial (LEAD-6). Lancet, The, 2009, 374, 39-47.	6.3	1,324
2	Liraglutide versus sitagliptin for patients with type 2 diabetes who did not have adequate glycaemic control with metformin: a 26-week, randomised, parallel-group, open-label trial. Lancet, The, 2010, 375, 1447-1456.	6.3	534
3	Scientific evidence on the links between periodontal diseases and diabetes: Consensus report and guidelines of the joint workshop on periodontal diseases and diabetes by the International Diabetes Federation and the European Federation of Periodontology. Journal of Clinical Periodontology, 2018, 45, 138-149.	2.3	384
4	Â-Cell Death and Mass in Syngeneically Transplanted Islets Exposed to Short- and Long-Term Hyperglycemia. Diabetes, 2002, 51, 66-72.	0.3	383
5	Oral Semaglutide Versus Empagliflozin in Patients With Type 2 Diabetes Uncontrolled on Metformin: The PIONEER 2 Trial. Diabetes Care, 2019, 42, 2272-2281.	4.3	225
6	One year of liraglutide treatment offers sustained and more effective glycaemic control and weight reduction compared with sitagliptin, both in combination with metformin, in patients with type 2 diabetes: a randomised, parallel-group, open-label trial. International Journal of Clinical Practice, 2011, 65, 397-407.	0.8	221
7	Linear correlation between beta-cell mass and body weight throughout the lifespan in Lewis rats: role of beta-cell hyperplasia and hypertrophy. Diabetes, 2000, 49, 1341-1346.	0.3	189
8	Scientific evidence on the links between periodontal diseases and diabetes: Consensus report and guidelines of the joint workshop on periodontal diseases and diabetes by the International diabetes Federation and the European Federation of Periodontology. Diabetes Research and Clinical Practice, 2018, 137, 231-241.	1.1	173
9	Switching to Once-Daily Liraglutide From Twice-Daily Exenatide Further Improves Glycemic Control in Patients With Type 2 Diabetes Using Oral Agents. Diabetes Care, 2010, 33, 1300-1303.	4.3	163
10	A review of efficacy and safety data regarding the use of liraglutide, a once-daily human glucagon-like peptide 1 analogue, in the treatment of type 2 diabetes mellitus. Clinical Therapeutics, 2009, 31, 2472-2488.	1.1	96
11	Incidence of diabetes mellitus in Spain as results of the nation-wide cohort di@bet.es study. Scientific Reports, 2020, 10, 2765.	1.6	71
12	A Randomized Comparison of Reservoir-Based Polymer-Free Amphilimus-Eluting Stents Versus Everolimus-Eluting Stents With Durable Polymer in Patients With DiabetesÂMellitus. JACC: Cardiovascular Interventions, 2016, 9, 42-50.	1.1	68
13	Report from IPITA-TTS Opinion Leaders Meeting on the Future of Î²-Cell Replacement. Transplantation, 2016, 100, S1-S44.	0.5	66
14	Interleukin-1Î² and inducible form of nitric oxide synthase expression in early syngeneic islet transplantation. Journal of Endocrinology, 2007, 192, 169-177.	1.2	64
15	Efficacy and Safety of Switching From the DPP-4 Inhibitor Sitagliptin to the Human GLP-1 Analog Liraglutide After 52 Weeks in Metformin-Treated Patients With Type 2 Diabetes. Diabetes Care, 2012, 35, 1986-1993.	4.3	58
16	Adenoviral overexpression of interleukin-1 receptor antagonist protein increases Î²-cell replication in rat pancreatic islets. Gene Therapy, 2005, 12, 120-128.	2.3	52
17	Gastrin Treatment Stimulates Î²-Cell Regeneration and Improves Glucose Tolerance in 95% Pancreatectomized Rats. Endocrinology, 2011, 152, 2580-2588.	1.4	43
18	Pancreatic Remodeling: Beta-Cell Apoptosis, Proliferation and Neogenesis, and the Measurement of Beta-Cell Mass and of Individual Beta-Cell Size. Methods in Molecular Biology, 2009, 560, 137-158.	0.4	39

#	Article	IF	Citations
19	Improved outcome of islet transplantation in insulin-treated diabetic mice: effects on beta-cell mass and function. Diabetologia, 1997, 40, 1004-1010.	2.9	37
20	Adenoviral overproduction of interleukin-1 receptor antagonist increases beta cell replication and mass in syngeneically transplanted islets, and improves metabolic outcome. Diabetologia, 2007, 50, 602-611.	2.9	36
21	Validation of selfâ€reported measures of periodontitis in a Spanish Population. Journal of Periodontal Research, 2020, 55, 400-409.	1.4	32
22	Optimal Insulin Treatment in Syngeneic Islet Transplantation. Cell Transplantation, 2000, 9, 11-18.	1.2	31
23	Comparison of liraglutide versus other incretinâ€related antiâ€hyperglycaemic agents. Diabetes, Obesity and Metabolism, 2012, 14, 20-32.	2.2	29
24	Gastrin induces ductal cell dedifferentiation and Î²-cell neogenesis after 90% pancreatectomy. Journal of Endocrinology, 2014, 223, 67-78.	1.2	29
25	Short-Term Culture with the Caspase Inhibitor z-VAD.fmk Reduces Beta Cell Apoptosis in Transplanted Islets and Improves the Metabolic Outcome of the Graft. Cell Transplantation, 2005, 14, 59-65.	1.2	28
26	Normoglycemia Restores Î²-Cell Replicative Response to Glucose in Transplanted Islets Exposed to Chronic Hyperglycemia. Diabetes, 1998, 47, 192-196.	0.3	26
27	A comparison of currently available GLP-1 receptor agonists for the treatment of type 2 diabetes. Expert Opinion on Pharmacotherapy, 2012, 13, 1451-1467.	0.9	25
28	Metformin extendedâ€release versus immediateâ€release: <scp>A</scp>n international, randomized, doubleâ€blind, headâ€toâ€head trial in pharmacotherapyâ€naÃ¯ve patients with type 2 diabetes. Diabetes, Obesity and Metabolism, 2018, 20, 463-467.	2.2	25
29	Selection of a Suitable Internal Control Gene for Expression Studies in Pancreatic Islet Grafts. Transplantation, 2005, 80, 650-652.	0.5	24
30	Fasting plasma glucose is an independent predictor of survival in patients with locally advanced non-small cell lung cancer treated with concurrent chemoradiotherapy. BMC Cancer, 2019, 19, 165.	1.1	24
31	Scientific evidence on the links between periodontal diseases and diabetes: consensus report and guidelines of the joint workshop on periodontal diseases and diabetes by the international Diabetes Federation (IDF) and the European Federation of Periodonto. Journal of Clinical Periodontology, 2018, 45, 138.	2.3	24
32	Increased Î²-Cell Replication and Î²-Cell Mass Regeneration in Syngeneically Transplanted Rat Islets Overexpressing Insulin-Like Growth Factor II. Cell Transplantation, 2012, 21, 2119-2129.	1.2	22
33	Islet- and stem-cell-based tissue engineering in diabetes. Current Opinion in Biotechnology, 2004, 15, 435-440.	3.3	21
34	Insulin Resistance Compensation: Not Just a Matter of Â-Cells?. Diabetes, 2014, 63, 832-834.	0.3	21
35	Role of Blood Glucose in Cytokine Gene Expression in Early Syngeneic Islet Transplantation. Cell Transplantation, 2007, 16, 517-525.	1.2	17
36	High sensitivity of Î²-cell replication to the inhibitory effects of interleukin-1Î²: modulation by adenoviral overexpression of IGF2 in rat islets. Journal of Endocrinology, 2009, 203, 55-63.	1.2	16

#	Article	IF	Citations
37	Î²-Cell dedifferentiation, reduced duct cell plasticity, and impaired Î²-cell mass regeneration in middle-aged rats. American Journal of Physiology - Endocrinology and Metabolism, 2016, 311, E554-E563.	1.8	16
38	Human Serum versus Human Serum Albumin Supplementation in Human Islet Pretransplantation Culture: In Vitro and in Vivo Assessment. Cell Transplantation, 2016, 25, 343-352.	1.2	16
39	Liraglutide Achieves A1C Targets More often than Sitagliptin or Exenatide when Added to Metformin in Patients with Type 2 Diabetes and a Baseline A1C <8.0%. Endocrine Practice, 2013, 19, 64-72.	1.1	15
40	A Model for Human Islet Transplantation to Immunodeficient Streptozotocin-Induced Diabetic Mice. Cell Transplantation, 2018, 27, 1684-1691.	1.2	15
41	Epithelial to mesenchymal transition in human endocrine islet cells. PLoS ONE, 2018, 13, e0191104.	1.1	15
42	Islet Graft Response to Transplantation Injury Includes Upregulation of Protective as Well as Apoptotic Genes. Cell Transplantation, 2008, 17, 1025-1034.	1.2	14
43	Histological changes in endocrine and exocrine pancreatic tissue from patients exposed to incretinâ€based therapies. Diabetes, Obesity and Metabolism, 2016, 18, 1253-1262.	2.2	13
44	Glucose-Dependent Changes in SNARE Protein Levels in Pancreatic Î²-Cells. Endocrinology, 2011, 152, 1290-1299.	1.4	12
45	Inhibition of connexin 36 hemichannels by glucose contributes to the stimulation of insulin secretion. American Journal of Physiology - Endocrinology and Metabolism, 2014, 306, E1354-E1366.	1.8	12
46	Efficacy and safety of oral semaglutide by subgroups of patient characteristics in the <scp>PIONEER</scp> phase 3 programme. Diabetes, Obesity and Metabolism, 2022, 24, 1338-1350.	2.2	12
47	Improvement in glycated haemoglobin evaluated by baseline body mass index: a metaâ€analysis of the liraglutide phase <scp>III</scp> clinical trial programme. Diabetes, Obesity and Metabolism, 2016, 18, 707-710.	2.2	10
48	Digital intervention increases influenza vaccination rates for people with diabetes in a decentralized randomized trial. Npj Digital Medicine, 2021, 4, 138.	5.7	10
49	A Role for the Host in the Roadmap to Diabetes Stem Cell Therapy. Diabetes, 2016, 65, 1155-1157.	0.3	9
50	Rationale and study design of the <scp>RESERVOIR</scp> trial: A randomized trial comparing reservoirâ€based polymerâ€free amphilimusâ€eluting stents versus everolimusâ€eluting stents with durable polymer in patients with diabetes mellitus. Catheterization and Cardiovascular Interventions, 2015, 85, E116-22.	0.7	8
51	Limited Joint Mobility Progression in Type 1 Diabetes: A 15-Year Follow-Up Study. International Journal of Endocrinology, 2018, 2018, 1-5.	0.6	6
52	Pancreatic ductal cells may have a negative effect on human islet transplantation. PLoS ONE, 2019, 14, e0220064.	1.1	5
53	Cortistatin regulates glucose-induced electrical activity and insulin secretion in mouse pancreatic beta-cells. Molecular and Cellular Endocrinology, 2019, 479, 123-132.	1.6	5
54	Fatty liver index as a predictor for type 2 diabetes in subjects with normoglycemia in a nationwide cohort study. Scientific Reports, 2021, 11, 16453.	1.6	5

#	Article	IF	Citations
55	Determining Beta Cell Mass, Apoptosis, Proliferation, and Individual Beta Cell Size in Pancreatic Sections. Methods in Molecular Biology, 2020, 2128, 313-337.	0.4	5
56	Optimization of Human Pancreatic Islet Isolation With a Newly Designed Cooling System for COBE 2991. Transplantation Proceedings, 2009, 41, 2202-2203.	0.3	3
57	Purification of replicating pancreatic Î²-cells for gene expression studies. Scientific Reports, 2017, 7, 17515.	1.6	3
58	In Vivo Evaluation of the Synergic Effect of Metformin and mTOR Inhibitors on the Endothelial Healing of Drug-eluting Stents in Diabetic Patients. Revista Espanola De Cardiologia (English Ed), 2018, 71, 917-925.	0.4	3
59	Engineering pancreatic islets. Pflugers Archiv European Journal of Physiology, 2000, 440, 1.	1.3	3
60	Use of Streptozotocin in Rodent Models of Islet Transplantation. Methods in Molecular Biology, 2020, 2128, 135-147.	0.4	3
61	Fibronectin Enhances Soluble N-ethylmaleimide-Sensitive Factor Attachment Protein Receptor Protein Expression in Cultured Human Islets. Pancreas, 2011, 40, 1153-1155.	0.5	2
62	A1C Improvement with Liraglutide Evaluated by Baseline BMI. Canadian Journal of Diabetes, 2013, 37, S35-S36.	0.4	2
63	EvaluaciÃ³n del efecto sinÃ©rgico de la metformina y los inhibidores mTOR sobre la endotelizaciÃ³n de los stents farmacoactivos en pacientes diabÃ©ticos. Revista Espanola De Cardiologia, 2018, 71, 917-925.	0.6	2
64	Future and emerging therapies. , 2016, , 77-92.		1
65	Relevancia de las caracterÃsticas del inmunoanÃ¡lisis para insulina en la hipoglucemia facticia. Endocrinologia, Diabetes Y NutriciÃ“n, 2018, 65, 306-307.	0.1	1
66	Incidence and regression of metabolic syndrome in a representative sample of the Spanish population: results of the cohort di@bet.es study. BMJ Open Diabetes Research and Care, 2020, 8, .	1.2	1
67	The Atrial Natriuretic Peptide and Guanylyl Cyclase-A System Modulates Pancreatic Î²-Cell Function. Journal of Clinical Endocrinology and Metabolism, 2010, 95, 3561-3562.	1.8	0
68	Patients Treated with Liraglutide Are More Likely to Reach Target HbA1c Compared with Sitagliptin or Exenatide BID. Canadian Journal of Diabetes, 2012, 36, S45-S46.	0.4	0
69	MA06.07 Impact of Type 2 Diabetes Mellitus and Its Metabolic Control on Prognosis of Unresectable Non-Small Cell Lung Cancer Patients. Journal of Thoracic Oncology, 2017, 12, S373.	0.5	0
70	Hemorragia adrenal bilateral metacrÃ³nica en el sÃ¬ndrome antifosfolipÃ¡dico primario. Medicina ClÃ¬nica, 2017, 149, 318.	0.3	0
71	Metachronous bilateral adrenal hemorrhage in primary antiphospholipid syndrome. Medicina ClÃ¬nica (English Edition), 2017, 149, 318.	0.1	0